Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A.

Tarantino MD, Collins PW, Hay CR, Shapiro AD, Gruppo RA, Berntorp E, Bray GL, Tonetta SA, Schroth PC, Retzios AD, Rogy SS, Sensel MG, Ewenstein BM; RAHF-PFM Clinical Study Group.

Haemophilia. 2004 Sep;10(5):428-37.

PMID:
15357767
2.

Hemophilia therapy innovation: development of an advanced category recombinant factor VIII by a plasma/albumin-free method. Proceedings of a Special Symposium at the XIXth Congress of the International Society on Thrombosis and Haemostasis, July 12-18, 2003, Birmingham, UK.

Ewenstein BM, Collins P, Tarantino MD, Negrier C, Blanchette V, Shapiro AD, Baker D, Spotts G, Sensel M, Yi SE, Gomperts ED.

Semin Hematol. 2004 Jan;41(1 Suppl 2):1-16; discussion 16-8.

PMID:
15071785
3.

Fibrolamellar hepatocellular carcinoma in children and adolescents.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC.

Cancer. 2003 Apr 15;97(8):2006-12. Review.

4.

Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Bostrom BC, Sensel MR, Sather HN, Gaynon PS, La MK, Johnston K, Erdmann GR, Gold S, Heerema NA, Hutchinson RJ, Provisor AJ, Trigg ME; Children's Cancer Group.

Blood. 2003 May 15;101(10):3809-17. Epub 2003 Jan 16.

5.

Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study.

Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Newman K, Finegold MJ, Haas JE, Sensel MG, Castleberry RP, Bowman LC.

J Clin Oncol. 2002 Jun 15;20(12):2789-97.

PMID:
12065555
6.

Abnormalities of chromosome bands 15q13-15 in childhood acute lymphoblastic leukemia.

Heerema NA, Sather HN, Sensel MG, La MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM.

Cancer. 2002 Feb 15;94(4):1102-10.

7.

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Lange BJ, Bostrom BC, Cherlow JM, Sensel MG, La MK, Rackoff W, Heerema NA, Wimmer RS, Trigg ME, Sather HN; Children's Cancer Group.

Blood. 2002 Feb 1;99(3):825-33.

8.

Bone marrow leukemic progenitor cell content in pediatric T-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.

Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Willoughby M.

Leuk Lymphoma. 2001 Jan;40(3-4):279-85.

PMID:
11426549
9.

Duration of hospitalization as a measure of cost on Children's Cancer Group acute lymphoblastic leukemia studies.

Gaynon PS, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB, Steinherz PG, Sensel MG, Lee MK, Stram DO, Sather HN.

J Clin Oncol. 2001 Apr 1;19(7):1916-25.

PMID:
11283123
10.

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

Gaynon PS, Trigg ME, Heerema NA, Sensel MG, Sather HN, Hammond GD, Bleyer WA.

Leukemia. 2000 Dec;14(12):2223-33.

PMID:
11187913
11.

Abnormalities of chromosome bands 13q12 to 13q14 in childhood acute lymphoblastic leukemia.

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson RJ, Nachman JB, Reaman GH, Lange BJ, Steinherz PG, Bostrom BC, Gaynon PS, Uckun FM.

J Clin Oncol. 2000 Nov 15;18(22):3837-44.

PMID:
11078497
12.

Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.

Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, Sensel M, Reaman GH, Gaynon PS.

Clin Cancer Res. 2000 Aug;6(8):3123-30.

13.

Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group.

Ortega JA, Douglass EC, Feusner JH, Reynolds M, Quinn JJ, Finegold MJ, Haas JE, King DR, Liu-Mares W, Sensel MG, Krailo MD.

J Clin Oncol. 2000 Jul;18(14):2665-75.

PMID:
10894865
14.

Prognostic impact of trisomies of chromosomes 10, 17, and 5 among children with acute lymphoblastic leukemia and high hyperdiploidy (> 50 chromosomes).

Heerema NA, Sather HN, Sensel MG, Zhang T, Hutchinson RJ, Nachman JB, Lange BJ, Steinherz PG, Bostrom BC, Reaman GH, Gaynon PS, Uckun FM.

J Clin Oncol. 2000 May;18(9):1876-87.

PMID:
10784628
15.

Clinical significance of deletions of chromosome arm 6q in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Gaynon PS, Uckun FM.

Leuk Lymphoma. 2000 Feb;36(5-6):467-78.

PMID:
10784391
16.

Prognostic significance of cytogenetic abnormalities of chromosome arm 12p in childhood acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Lee MK, Hutchinson R, Nachman JB, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun FM.

Cancer. 2000 Apr 15;88(8):1945-54.

PMID:
10760773
17.

Hypodiploidy with less than 45 chromosomes confers adverse risk in childhood acute lymphoblastic leukemia: a report from the children's cancer group.

Heerema NA, Nachman JB, Sather HN, Sensel MG, Lee MK, Hutchinson R, Lange BJ, Steinherz PG, Bostrom B, Gaynon PS, Uckun F.

Blood. 1999 Dec 15;94(12):4036-45.

18.

Expression of aberrantly spliced oncogenic ikaros isoforms in childhood acute lymphoblastic leukemia.

Sun L, Goodman PA, Wood CM, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Vassilev A, Juran BD, Reaman GH, Uckun FM.

J Clin Oncol. 1999 Dec;17(12):3753-66.

PMID:
10577847
19.

Paucity of leukemic progenitor cells in the bone marrow of pediatric B-lineage acute lymphoblastic leukemia patients with an isolated extramedullary first relapse.

Uckun FM, Gaynon PS, Stram DO, Sensel MG, Sarquis MB, Lazarus KH, Willoughby M.

Clin Cancer Res. 1999 Sep;5(9):2415-20.

20.

Association of chromosome arm 9p abnormalities with adverse risk in childhood acute lymphoblastic leukemia: A report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Liu-Mares W, Lange BJ, Bostrom BC, Nachman JB, Steinherz PG, Hutchinson R, Gaynon PS, Arthur DC, Uckun FM.

Blood. 1999 Sep 1;94(5):1537-44.

21.

Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia.

Sun L, Crotty ML, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Mao C, Vassilev A, Reaman GH, Uckun FM.

Clin Cancer Res. 1999 Aug;5(8):2112-20.

22.

Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy.

Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA.

Leuk Lymphoma. 1999 Mar;33(1-2):101-6.

PMID:
10194126
23.

Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.

Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, Leonard M, Holmes EJ, Sather HN, Pendergrass TW, Johnstone HS, O'Brien RT, Steinherz PG, Zeltzer PM, Gaynon PS, Trigg ME, Uckun FM.

J Clin Oncol. 1999 Feb;17(2):445-55.

PMID:
10080584
24.

Prognostic significance of T-lineage leukemic cell growth in SCID mice: a Children's Cancer Group study.

Uckun FM, Waurzyniak BJ, Sather HN, Sensel MG, Chelstrom L, Nachman J, Gaynon PS, Bostrom B, Ek O, Sarquis M, Steinherz PG, Reaman GH.

Leuk Lymphoma. 1999 Feb;32(5-6):475-87.

PMID:
10048420
25.

Distinct in vivo engraftment and growth patterns of t(1;19)+/E2A-PBX1+ and t(9;22)+/BCR-ABL+ human leukemia cells in SCID mice.

Waurzyniak BJ, Heerema N, Sensel MG, Gaynon PS, Kraft P, Sather HN, Chelstrom L, Reaman GH, Uckun FM.

Leuk Lymphoma. 1998 Dec;32(1-2):77-87.

PMID:
10037003
26.

Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia.

Sun L, Heerema N, Crotty L, Wu X, Navara C, Vassilev A, Sensel M, Reaman GH, Uckun FM.

Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):680-5.

27.

Clinical significance of Philadelphia chromosome positive pediatric acute lymphoblastic leukemia in the context of contemporary intensive therapies: a report from the Children's Cancer Group.

Uckun FM, Nachman JB, Sather HN, Sensel MG, Kraft P, Steinherz PG, Lange B, Hutchinson R, Reaman GH, Gaynon PS, Heerema NA.

Cancer. 1998 Nov 1;83(9):2030-9.

PMID:
9806664
28.

Primary blasts from infants with acute lymphoblastic leukemia cause overt leukemia in SCID mice.

Uckun FM, Waurzyniak BJ, Sensel MG, Chelstrom L, Crotty ML, Gaynon PS, Reaman GH.

Leuk Lymphoma. 1998 Jul;30(3-4):269-77.

PMID:
9713959
29.

Prognostic significance of B-lineage leukemic cell growth in SCID mice: a Children's Cancer Group Study.

Uckun FM, Sather HN, Waurzyniak BJ, Sensel MG, Chelstrom L, Ek O, Sarquis MB, Nachman J, Bostrom B, Reaman GH, Gaynon PS.

Leuk Lymphoma. 1998 Aug;30(5-6):503-14.

PMID:
9711913
30.

Clinical significance of MLL-AF4 fusion transcript expression in the absence of a cytogenetically detectable t(4;11)(q21;q23) chromosomal translocation.

Uckun FM, Herman-Hatten K, Crotty ML, Sensel MG, Sather HN, Tuel-Ahlgren L, Sarquis MB, Bostrom B, Nachman JB, Steinherz PG, Gaynon PS, Heerema N.

Blood. 1998 Aug 1;92(3):810-21.

31.

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy.

Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS.

N Engl J Med. 1998 Jun 4;338(23):1663-71.

32.

Frequency and clinical significance of cytogenetic abnormalities in pediatric T-lineage acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Heerema NA, Sather HN, Sensel MG, Kraft P, Nachman JB, Steinherz PG, Lange BJ, Hutchinson RS, Reaman GH, Trigg ME, Arthur DC, Gaynon PS, Uckun FM.

J Clin Oncol. 1998 Apr;16(4):1270-8.

PMID:
9552025
33.

Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group.

Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, Wolff L, Trigg ME.

J Clin Oncol. 1998 Mar;16(3):920-30.

PMID:
9508174
34.
35.

Prognostic significance of the CD10+CD19+CD34+ B-progenitor immunophenotype in children with acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Uckun FM, Sather H, Gaynon P, Arthur D, Nachman J, Sensel M, Steinherz P, Hutchinson R, Trigg M, Reaman G.

Leuk Lymphoma. 1997 Nov;27(5-6):445-57.

PMID:
9477126
36.

Clinical significance of translocation t(1;19) in childhood acute lymphoblastic leukemia in the context of contemporary therapies: a report from the Children's Cancer Group.

Uckun FM, Sensel MG, Sather HN, Gaynon PS, Arthur DC, Lange BJ, Steinherz PG, Kraft P, Hutchinson R, Nachman JB, Reaman GH, Heerema NA.

J Clin Oncol. 1998 Feb;16(2):527-35.

PMID:
9469337
37.

Biology and treatment of childhood T-lineage acute lymphoblastic leukemia.

Uckun FM, Sensel MG, Sun L, Steinherz PG, Trigg ME, Heerema NA, Sather HN, Reaman GH, Gaynon PS.

Blood. 1998 Feb 1;91(3):735-46. Review. No abstract available.

38.

Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group.

Uckun FM, Sather HN, Gaynon PS, Arthur DC, Trigg ME, Tubergen DG, Nachman J, Steinherz PG, Sensel MG, Reaman GH.

Blood. 1997 Jul 1;90(1):28-35.

39.

Clinical features and treatment outcome of childhood T-lineage acute lymphoblastic leukemia according to the apparent maturational stage of T-lineage leukemic blasts: a Children's Cancer Group study.

Uckun FM, Gaynon PS, Sensel MG, Nachman J, Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN, Reaman GH.

J Clin Oncol. 1997 Jun;15(6):2214-21.

PMID:
9196133
40.

Clinical features and treatment outcome of children with biphenotypic CD2+ CD19+ acute lymphoblastic leukemia: a Children's Cancer Group study.

Uckun FM, Gaynon P, Sather H, Arthur D, Trigg M, Tubergen D, Nachman J, Steinherz P, Sensel MG, Reaman GR.

Blood. 1997 Apr 1;89(7):2488-93.

41.

Engineering novel antibody molecules.

Sensel MG, Coloma MJ, Harvill ET, Shin SU, Smith RI, Morrison SL.

Chem Immunol. 1997;65:129-58. Review. No abstract available.

PMID:
9018876
43.

Isolation and characterization of clones for the rat hepatic lipase gene upstream regulatory region.

Sensel MG, Legrand-Lorans A, Wang ME, Bensadoun A.

Biochim Biophys Acta. 1990 Apr 6;1048(2-3):297-302.

PMID:
2322583
44.

Heparin decreases the degradation rate of hepatic lipase in Fu5AH rat hepatoma cells. A model for hepatic lipase efflux from hepatocytes.

Cisar LA, Melford KH, Sensel M, Bensadoun A.

Biochim Biophys Acta. 1989 Aug 8;1004(2):196-204.

PMID:
2665815

Supplemental Content

Loading ...
Support Center